Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.36
+4.4%		$1.77
$1.09
▼
$3.40
$263.51M0.61.48 million shs728,095 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.11
+5.8%		$2.94
$1.66
▼
$4.54
$477.63M2.142.14 million shs2.11 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
0.00%+20.41%+58.39%+6.79%+7.27%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%+10.28%+13.92%+12.68%+16.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.36
+4.4%		$1.77
$1.09
▼
$3.40
$263.51M0.61.48 million shs728,095 shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.11
+5.8%		$2.94
$1.66
▼
$4.54
$477.63M2.142.14 million shs2.11 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
0.00%+20.41%+58.39%+6.79%+7.27%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%+10.28%+13.92%+12.68%+16.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.13
Hold$3.6353.60% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.57
Moderate Buy$5.5076.85% Upside

Current Analyst Ratings Breakdown

Latest EDIT and ALEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
8/13/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/31/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/27/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$21.05M12.52N/AN/A($0.09) per share-26.22
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$47.01M10.16N/AN/A$0.69 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$142.93M-$1.10N/AN/AN/A-850.13%-531.03%-44.00%11/5/2026 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$160.06M-$0.75N/AN/AN/A-157.32%-196.63%-38.17%11/9/2026 (Estimated)

Latest EDIT and ALEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2286-$0.21+$0.0186-$0.21$1.71 million$3.32 million
8/5/2026Q2 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.2705-$0.15+$0.1205-$0.15$2.85 million$11.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.80
5.26
5.26
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.19
3.19

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
8.30%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
270111.66 million102.39 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
230153.58 million148.82 millionOptionable

Recent News About These Companies

LADENBURG THALM/SH SH Begins Coverage on Editas Medicine (NASDAQ:EDIT)
August 20 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971332
Editas Medicine (NASDAQ:EDIT) Trading 14.4% Higher - Here's What Happened
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/editas-medicine-nasdaqedit-trading-144-higher-heres-what-happened-2026-08-19/
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/editas-medicine-nasdaqedit-coverage-initiated-at-ladenburg-thalmsh-sh-2026-08-18/
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-367147-shares-in-editas-medicine-inc-edit-bought-by-gsa-capital-partners-llp-2026-08-18/
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963386
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-given-average-recommendation-of-moderate-buy-by-analysts-2026-08-16/
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/editas-medicine-edit-outperforming-other-134002541.html
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971842/is-editas-medicine-edit-outperforming-other-medical-stocks-this-year?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_1-2971842
HC Wainwright Boosts Earnings Estimates for Editas Medicine
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-boosts-earnings-estimates-for-editas-medicine-2026-08-10/
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-editas-medicine-nasdaqedit-to-hold-2026-08-08/
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/edit-q2-earnings-beat-estimates-152600257.html
Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 6, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69233231-editas-medicine-inc-editas-medicine-announces-second-quarter-2026-results-and-business-updates-399.htm
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-announces-second-quarter-200100712.html
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-edit-reports-q2-221015487.html
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/editas-medicine-nasdaqedit-issues-earnings-results-2026-08-05/
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339644/0/en/editas-medicine-announces-second-quarter-2026-results-and-business-updates.html
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/geron-gern-reports-q2-loss-130005562.html
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/editas-medicine-strengthens-board-directors-201500842.html
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/editas-medicine-edit-projected-to-post-quarterly-earnings-on-tuesday-2026-08-04/
Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-raises-position-in-editas-medicine-inc-edit-2026-08-03/
Insider Selling: Editas Medicine (NASDAQ:EDIT) EVP Sells $13,157.76 in Stock
July 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-edit-insider-buying-and-selling-2026-07-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$2.36 +0.10 (+4.42%)
As of 08/21/2026 04:00 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$3.11 +0.17 (+5.78%)
As of 08/21/2026 04:00 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas